Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Infectious Disease IVD Sector Unaffected by Vaccine Development

By LabMedica International staff writers
Posted on 23 Dec 2013
A variety of factors will boost the infectious disease IVD market, even if vaccines are developed and widely distributed. More...


Shara Rosen, an analyst at the medical market research company, Kalorama Information (New York, NY, USA) and the author of a new report on the world market for infectious disease tests stated, ‘‘[....] in light of the recent reemergence of tuberculosis, measles, and malaria; and the persistence of polio, it is unrealistic to think that a disease could be totally eliminated around the world at the same time."

Vaccines have been successful in preventing disease, but Kalorama Information believes that does not mean they will upset the market for products to test for those diseases. The healthcare market research publisher says a variety of factors will boost the infectious disease IVD market, even if vaccines are developed and widely distributed. The world market for infectious disease tests is estimated at USD 14.5 billion in 2012, and with 5% Compound Annual Growth Rate (CAGR), will reach USD18.3 billion in 2017, according to their latest report.

In addition, pathogens constantly change their genetic make-up, which challenges the development of vaccines against infectious diseases. This genetic flexibility allows many infectious agents to mutate or evolve into more deadly strains against which humans have little or no resistance: the Human Immunodeficiency Virus (HIV) and influenza viruses, for example, constantly mutate and recombine to find their way through the host defense mechanisms. Finally, the vaccine market may not be strong enough to encourage enough entrants for all the possible infectious diseases. Even existing vaccine markets sometimes fail.

The flu epidemic scare of 2009 resulted in a shortage of flu vaccines, the industry prepared to avoid this in the future. However, things did not quite work out for them. In 2012, companies produced about 145 million doses and only about 129 million were distributed. In 2011, companies lost even more on the flu vaccine because it was such a light flu season and fewer people decided to get the shot.

Kalorama Information is a division of MarketResearch.com; it supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare; as well as a full range of custom research services.

Related Links:

Kalorama Information



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.